Melanocyte inducing transcription factor (MITF)

Melanocyte inducing transcription factor (MITF) is a basic helix–loop–helix leucine zipper transcription factor that acts as a master regulator for melanocyte lineage determination, differentiation, function and survival, as well as a key oncogene in melanoma[1][3][7][9]. MITF controls the expression of genes essential for melanin biosynthesis—including tyrosinase, TYRP1, DCT, and MLANA—in pigment cells and regulates pigment production in hair, eyes, and skin[1][7][9]. In addition to melanocytes, MITF is necessary for the development and function of retinal pigment epithelial cells, osteoclasts (bone resorption), mast cells (immunity/allergy), and even B cells in the immune system[1][5][7]. In melanoma, MITF plays an oncogenic role by modulating differentiation, cell cycle, survival, and proliferation signals, and abnormal MITF expression or mutation can promote tumor progression or confer resistance to therapies[7][9]. MITF is also implicated in several genetic syndromes involving pigmentary and auditory defects, such as Waardenburg syndrome and Tietz syndrome[1][4][7]. Multiple isoforms exist, with MITF-M being melanocyte-specific[4][7]. Several drugs (mainly research compounds) that modulate MITF activity are under investigation, but its role in diverse physiological processes creates therapeutic challenges and potential safety risks if targeted[5][9].

Other names

Microphthalmia-associated transcription factorbHLHe32Class E basic helix–loop–helix protein 32MICMM8COMMADMITF-AWS2WS2Amelanogenesis associated transcription factormicrophtalmia-associated transcription factorhomolog of mouse microphthalmiamelanocyte-inducing transcription factorMITF-MMITF-BMITF-CMITF-H

Direct inhibition of MITF DNA binding or transcriptional activity; Modulation of MITF phosphorylation and stability via upstream signaling (e.g., MAPK, mTOR, PKC pathways)